NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2
November 18, 2024 07:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18 November 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2
November 18, 2024 01:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18 November 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
July 11, 2024 07:00 ET
|
NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
July 11, 2024 01:00 ET
|
NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 07:00 ET
|
NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
June 20, 2023 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan...
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
March 08, 2023 11:20 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
January 25, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023 ...
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
November 09, 2022 16:11 ET
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7...
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
February 17, 2022 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing...